Evidence map›Paper›PMID 40274225›Full record

ArticleJournal of advanced research2026

Niclosamide extends health span and reduces frailty by ameliorating mTORC1 hyperactivation in aging models.

Pyeong Geun Choi, Hee Soo Kim, So-Hyun Park, Hyo-Deok Seo, Jeong-Hoon Hahm, Yang Hoon Huh, Tae-Il Jeon, Jiyun Ahn, Chang Hwa Jung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pyeong Geun ChoiAging Research Group, Korea Food Research Institute, Wanju-gun, Republic of Korea; Department of Food Biotechnology, Korea University of Science and Technology, Wanju-gun, Republic of Korea.
Hee Soo KimAging Research Group, Korea Food Research Institute, Wanju-gun, Republic of Korea; Department of Food Biotechnology, Korea University of Science and Technology, Wanju-gun, Republic of Korea.
So-Hyun ParkAging Research Group, Korea Food Research Institute, Wanju-gun, Republic of Korea.
Hyo-Deok SeoAging Research Group, Korea Food Research Institute, Wanju-gun, Republic of Korea.
Jeong-Hoon HahmAging Research Group, Korea Food Research Institute, Wanju-gun, Republic of Korea.
Yang Hoon HuhCenter for Electron Microscopy Research, Korea Basic Science Institute, Cheongju, Republic of Korea.
Tae-Il JeonDepartment of Animal Science, Chonnam National University, Gwangju, Republic of Korea.
Jiyun AhnAging Research Group, Korea Food Research Institute, Wanju-gun, Republic of Korea; Department of Food Biotechnology, Korea University of Science and Technology, Wanju-gun, Republic of Korea.
Chang Hwa JungAging Research Group, Korea Food Research Institute, Wanju-gun, Republic of Korea; Department of Food Biotechnology, Korea University of Science and Technology, Wanju-gun, Republic of Korea. Electronic address: chjung@kfri.re.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFrailty is characterized by an increased vulnerability to disease and physical debilitation due to a decline in the body's capacity to maintain homeostasis during aging. Therefore, effective management of frailty is crucial for promoting health. Although the role of niclosamide (NIC), an autophagy promoter, has been studied for the treatment of cancer, infectious diseases, and metabolic disorders, no research has focused on its effects on aging.

objectivesIn this study, we aimed to evaluate the effects of NIC on the aging process and assess its potential as a novel anti-aging therapeutic agent.

methodsWe evaluated the effects of NIC on frailty, physical function, and metabolic function using Caenorhabditis elegans (C. elegans) and aging mouse models. NIC effectiveness was assessed using behavioral experiments, histological analysis, and molecular biological analysis.

resultsWe identified NIC as a compound that enhanced exercise capacity and metabolism, thereby alleviating frailty. Briefly, NIC extended the lifespan and improved frailty-related phenotypes in C. elegans, and effectively ameliorated frailty in aging mice, particularly in muscle aging. Additionally, NIC treatment suppressed the muscle atrophy-related ubiquitin-proteasome system induced by mammalian target of rapamycin complex 1 (mTORC1) hyperactivation, while enhancing autophagic flux, another aspect of proteostasis. Furthermore, mRNA-seq analysis revealed that NIC improved metabolism-related functions.

conclusionCollectively, these findings suggest that NIC is a promising novel candidate for the prevention of frailty.

Indexed as

AgingFrailtyLongevityMechanistic Target of Rapamycin Complex 1NiclosamideAnimalsAutophagyCaenorhabditis elegansDisease Models, AnimalMaleMiceMechanistic Target of Rapamycin Complex 1NiclosamideAgingCaenorhabditis elegansHealth spanLongevitySarcopeniaSkeletal muscle

Identifiers

PMID40274225
PMCPMC12869201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.